Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biondvax Pharma ADR (NQ: BVXV )

N/A UNCHANGED
Last Price Updated: 3:59 PM EDT, Sep 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biondvax Pharma ADR

< Previous 1 2 3 4 5 6 7 8 9 Next >
BC Study Uncovers Cause of Four Major Pediatric Allergies
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Rebrands as Scinai Immunotherapeutics Ltd.
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
Scinai Immunotherapeutics to debut tomorrow under Nasdaq ticker symbol “SCNI” 
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
Shining the Spotlight on Asthma During Pregnancy
Via Investor Brand Network
Study Links Gut Flora to Onset of Pediatric Rheumatism
Via Investor Brand Network
BioMedNewsBreaks — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs
Via Investor Brand Network
Exposures Product Safety
Malaria Case Prompts Army to Ask Infectious Disease Experts to Analyze Mosquitoes
Via Investor Brand Network
England Sees Soaring Numbers of Hospitalizations for Severe Allergies
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is Fast on the Trail to Target IL-17
Via Investor Brand Network
How Allergy Sufferers Can Benefit from Immunotherapy
Via Investor Brand Network
Analyzing Link Between Hormonal Contraceptives, Autoimmunity
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Advances NanoAb Therapy as IL-17 Drug Candidate for Psoriasis Treatment
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update
Via Investor Brand Network
Stem Cell Transplants Followed by Immunotherapy Show Efficacy Against Pediatric Nerve Tumors
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Alpaca-Derived Nanobodies for Potential Treatment of Diseases Underserved by Current Therapeutics
Via Investor Brand Network
Exposures COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update
Via Investor Brand Network
Exposures COVID-19
BiondVax Reports Second Quarter Financial Results and Provides Business Update
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
How Immunotherapy Outcomes Can Be Affected by Diet, Gut Microbiota
Via Investor Brand Network
Study Finds Link Between Food Allergies in Infants, Childhood Asthma Onset
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Granted Extension to Regain NASDAQ Compliance
Via Investor Brand Network
Exposures COVID-19
Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Unique NanoAb Pipeline to Target Large, Growing Markets
Via Investor Brand Network
Review Shows AI Could Be Pivotal in Infectious Disease Prevention
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
M&A Activity, Booming Sales of Anti-IL-17 Drugs Suggest Strong Upside Potential for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) CDMO Services Designed to Meet Needs of Pharmaceutical, Biotechnology Companies of All Sizes
Via Investor Brand Network
Exposures COVID-19
Psoriasis Could Be Behind Frequent Fatigue
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Amir Reichman Featured on IBN’s The Bell2Bell Podcast
Via Investor Brand Network
Exposures COVID-19
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Sees Hot Market Potential for NanoAb Pipeline
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Bell2Bell Podcast
Via Investor Brand Network
Study Concludes That Long COVID Should Be Treated Holistically
Via Investor Brand Network
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.